MCID: MLG064
MIFTS: 45

Malignant Ependymoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Malignant Ependymoma

MalaCards integrated aliases for Malignant Ependymoma:

Name: Malignant Ependymoma 12 15
Ependymal Tumors 12 55
Experimental Organism Malignant Ependymoma 73
Anaplastic Ependymoma 73
Ependymoma of Brain 73
Ependymal Neoplasm 12
Ependymal Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5074
NCIt 50 C6770

Summaries for Malignant Ependymoma

Disease Ontology : 12 A malignant glioma that is derived from ependymal cells, a type of glial cell, located in ventricle lining within the central part of the brain.

MalaCards based summary : Malignant Ependymoma, also known as ependymal tumors, is related to benign ependymoma and ependymoma, and has symptoms including headache, nausea and seizures. An important gene associated with Malignant Ependymoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways is DNA damage_ATM/ATR regulation of G1/S checkpoint. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include ventricle lining, brain and bone, and related phenotypes are Increased proliferation and immune system

Related Diseases for Malignant Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Malignant Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 benign ependymoma 32.5 GFAP NF2
2 ependymoma 30.5 GFAP NF2 RELA
3 subependymal glioma 11.0
4 brain ependymoma 11.0
5 intraventricular meningioma 10.7 GFAP NF2
6 cornea cancer 10.7 GFAP NF2
7 rhabdoid meningioma 10.7 GFAP NF2
8 plexiform schwannoma 10.6 GFAP NF2
9 atypical neurofibroma 10.6 GFAP NF2
10 tanycytic ependymoma 10.6 GFAP NF2
11 olfactory groove meningioma 10.6 NF2 TP53
12 frontal convexity meningioma 10.6 GFAP TP53
13 gliofibroma 10.6 GFAP TP53
14 protoplasmic astrocytoma 10.6 GFAP TP53
15 central nervous system primitive neuroectodermal neoplasm 10.6 GFAP TP53
16 cerebral neuroblastoma 10.6 GFAP TP53
17 mixed glioma 10.5 GFAP TP53
18 ependymoblastoma 10.5 GFAP TP53
19 anterior cranial fossa meningioma 10.5 NF2 TP53
20 cerebral ventricle cancer 10.5 GFAP TP53
21 cerebrum cancer 10.5 GFAP TP53
22 cerebellopontine angle tumor 10.5 GFAP NF2
23 supratentorial cancer 10.5 GFAP TP53
24 small cell sarcoma 10.5 NF2 TP53
25 fibrillary astrocytoma 10.5 GFAP TP53
26 pleomorphic xanthoastrocytoma 10.5 GFAP TP53
27 gliomatosis cerebri 10.5 GFAP TP53
28 papilloma of choroid plexus 10.5 GFAP TP53
29 spinal cord astrocytoma 10.5 GFAP TP53
30 choroid plexus cancer 10.5 GFAP TP53
31 necrotizing sialometaplasia 10.5 GFAP TP53
32 cystic teratoma 10.4 GFAP TP53
33 optic nerve neoplasm 10.4 NF2 TP53
34 cerebellar liponeurocytoma 10.4 GFAP TP53
35 medullomyoblastoma 10.4 GFAP TP53
36 brain glioma 10.4 GFAP TP53
37 adult medulloblastoma 10.3 GFAP TP53
38 juvenile pilocytic astrocytoma 10.3 GFAP TP53
39 cellular schwannoma 10.3 NF2 TP53
40 optic nerve glioma 10.3 GFAP TP53
41 pineal gland cancer 10.3 GFAP PTPRS
42 giant cell glioblastoma 10.3 GFAP TP53
43 neurilemmoma 10.2 GFAP NF2
44 infratentorial cancer 10.2 GFAP TP53
45 cerebral convexity meningioma 10.2 GFAP NF2 TP53
46 spinal cancer 10.2 GFAP NF2 TP53
47 chordoid glioma 10.2 GFAP NF2 TP53
48 ganglioglioma 10.2 GFAP TP53
49 meningioma, familial 10.1 GFAP NF2 TP53
50 organ system benign neoplasm 10.1 NF2 TP53

Graphical network of the top 20 diseases related to Malignant Ependymoma:



Diseases related to Malignant Ependymoma

Symptoms & Phenotypes for Malignant Ependymoma

UMLS symptoms related to Malignant Ependymoma:


headache, nausea, seizures, vomiting

GenomeRNAi Phenotypes related to Malignant Ependymoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

MGI Mouse Phenotypes related to Malignant Ependymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.91 ERCC5 TP53 GFAP NF2 CD207 EPB41
2 digestive/alimentary MP:0005381 9.88 TP53 GFAP LOXL3 PTPRS RELA ERCC5
3 integument MP:0010771 9.8 TP53 LOXL3 NF2 PTPRS RELA ERCC5
4 mortality/aging MP:0010768 9.76 TP53 GFAP LOXL3 NF2 PTPRS EPB41
5 liver/biliary system MP:0005370 9.65 ERCC5 TP53 NF2 EPB41 RELA
6 respiratory system MP:0005388 9.35 TP53 LOXL3 NF2 PTPRS RELA
7 vision/eye MP:0005391 9.17 TP53 GFAP LOXL3 NF2 PTPRS ARVCF

Drugs & Therapeutics for Malignant Ependymoma

Drugs for Malignant Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Dopamine Approved Phase 3,Not Applicable 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
6 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
7 Analgesics Phase 3,Phase 2,Phase 1
8 Adjuvants, Anesthesia Phase 3
9 Central Nervous System Stimulants Phase 3,Phase 2
10 Cholinergic Agents Phase 3,Phase 2
11 Cholinesterase Inhibitors Phase 3,Phase 2
12 Narcotics Phase 3
13 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
14 Analgesics, Opioid Phase 3
15 Anesthetics Phase 3
16 Nootropic Agents Phase 3,Phase 2
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
20 Liver Extracts Phase 3,Phase 2,Phase 1
21 Dopamine Agents Phase 3,Not Applicable
22 Neurotransmitter Uptake Inhibitors Phase 3
23 Dexmethylphenidate Hydrochloride Phase 3
24 Dopamine Uptake Inhibitors Phase 3
25 Cola Nutraceutical Phase 3,Phase 1
26
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
27
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
28
Ethanol Approved Phase 1, Phase 2 64-17-5 702
29
Carmustine Approved, Investigational Phase 1, Phase 2,Phase 2 154-93-8 2578
30
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
31
Etoposide Approved Phase 2 33419-42-0 36462
32
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
33
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
34
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
35
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
36
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
37
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
38
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
39
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
40
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
41
Thiotepa Approved, Investigational Phase 2,Phase 1 52-24-4 5453
42 Piracetam Approved, Investigational Phase 2 7491-74-9
43
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
44
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
45
Tamoxifen Approved Phase 2 10540-29-1 2733526
46
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
47
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
48
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Armodafinil Approved, Investigational Phase 2 112111-43-0

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
5 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
6 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
7 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
8 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
9 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
10 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Completed NCT01836549 Phase 2 imetelstat sodium
11 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
12 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
13 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
14 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
15 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
16 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
17 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Completed NCT00352521 Phase 2 bevacizumab;irinotecan
18 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
19 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
20 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
21 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
22 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
23 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
24 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
25 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
26 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
27 Everolimus for Children With Recurrent or Progressive Ependymoma Recruiting NCT02155920 Phase 2 Everolimus
28 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Active, not recruiting NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
29 Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Active, not recruiting NCT01478321 Phase 2 Temozolomide
30 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
31 Antineoplaston Therapy in Treating Patients With Ependymoma Terminated NCT00003479 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
32 Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated NCT01095094 Phase 2 ritonavir;lopinavir
33 Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors Withdrawn NCT00243490 Phase 2
34 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
35 Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
36 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
37 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
38 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Gluco Completed NCT01082926 Phase 1
39 Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Completed NCT01234740 Phase 1 bafetinib
40 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1 Gamma-Secretase Inhibitor RO4929097;Cediranib Maleate
41 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
42 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
43 Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Completed NCT01480050 Phase 1 temozolomide;Mibefradil
44 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
45 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
46 Carmustine in Treating Patients With Recurrent Malignant Glioma Completed NCT00004028 Phase 1 carmustine
47 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
48 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
49 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
50 Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma Completed NCT00387933 Phase 1 hydroxyurea;imatinib mesylate;vatalanib

Search NIH Clinical Center for Malignant Ependymoma

Genetic Tests for Malignant Ependymoma

Anatomical Context for Malignant Ependymoma

The Foundational Model of Anatomy Ontology organs/tissues related to Malignant Ependymoma:

19
Ventricle Lining

MalaCards organs/tissues related to Malignant Ependymoma:

41
Brain, Bone, Bone Marrow, Liver, T Cells, Spinal Cord, Kidney

Publications for Malignant Ependymoma

Articles related to Malignant Ependymoma:

(show all 16)
# Title Authors Year
1
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( 21498732 )
2011
2
Cytologic findings in malignant ependymoma: a case report. ( 21053591 )
2010
3
Cachexia secondary to intracranial anaplastic (malignant) ependymoma in a boxer dog. ( 19796316 )
2009
4
A primary malignant ependymoma of the abdominal cavity: a case report and review of the literature. ( 19238432 )
2009
5
Sacrococcygeal immature teratoma with malignant ependymoma component. ( 19492320 )
2009
6
Supratentorial malignant ependymoma in childhood: 16 years without relapse after hemispherectomy. ( 15095106 )
2005
7
Primary malignant ependymoma of the lung. ( 1548954 )
1992
8
Extracranial metastases of malignant ependymoma--case report. ( 1699151 )
1990
9
Abnormal cilia in a malignant ependymoma. ( 3776464 )
1986
10
Acute leukaemia following malignant ependymoma: a case report. ( 3857395 )
1985
11
Subarachnoid haemorrhage due to widely metastatising malignant ependymoma. ( 4080060 )
1985
12
Malignant ependymoma involving the temporal bone with remote metastasis. ( 4429899 )
1974
13
Malignant ependymoma in a cat. ( 4731360 )
1973
14
Malignant ependymoma in a dog. ( 14497569 )
1962
15
Malignant Ependymoma Masquerading as Tuberculous Meningitis: Clinico-Pathological Conference. ( 28907958 )
1962
16
Malignant ependymoma infiltrating the scalp. ( 14810337 )
1951

Variations for Malignant Ependymoma

Expression for Malignant Ependymoma

Search GEO for disease gene expression data for Malignant Ependymoma.

Pathways for Malignant Ependymoma

Pathways related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.27 RELA TP53

GO Terms for Malignant Ependymoma

Biological processes related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide-excision repair GO:0006289 9.16 ERCC5 TP53
2 spinal cord development GO:0021510 8.96 LOXL3 PTPRS
3 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 8.62 RELA TP53

Molecular functions related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.65 ARVCF CD207 EPB41 ERCC5 GFAP LOXL3
2 protein N-terminus binding GO:0047485 8.92 EPB41 ERCC5 RELA TP53

Sources for Malignant Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....